AQP5 and xerostomia: In the treatment of LUTS, muscarinic antagonists contribute to the higher incidence of dry mouth compared with α1A-adrenergic antagonists, which may be correlated with proportionally higher stimulatory effect of mAChR agonists on AQP5 trafficking in parotid gland.